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Abstract
Background—HIV protein Nef plays a key role in impairing cholesterol metabolism in both 
HIV infected and bystander cells. The existence of a small cohort of patients infected with Nef-
deficient strain of HIV presented a unique opportunity to test the effect of Nef on lipid metabolism 
in a clinical setting.
Methods—Here we report the results of a study comparing six patients infected with Nef-
deficient strain of HIV (ΔNefHIV) with six treatment-naïve patients infected with wild-type HIV 
(WT HIV). Lipoprotein profile, size and functionality of high density lipoprotein (HDL) particles 
as well as lipidomic and microRNA profiles of patient plasma were analyzed.
Results—We found that patients infected with ΔNefHIV had lower proportion of subjects with 
plasma HDL-C levels <1 mmol/l compared to patients infected with WT HIV. Furthermore, 
compared to a reference group of HIV-negative subjects, there was higher abundance of smaller 
under-lipidated HDL particles in plasma of patients infected with WT HIV, but not in those 
infected with ΔNefHIV. Lipidomic analysis of plasma revealed differences in abundance of 
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phosphatidylserine and sphingolipids between patients infected with ΔNefHIV and WT HIV. 
MicroRNA profiling revealed that plasma abundance of 24 miRNAs, many of those involved in 
regulation of lipid metabolism, was differentially regulated by WT HIV and ΔNefHIV.
Conclusion—Our findings are consistent with HIV protein Nef playing a significant role in 
pathogenesis of lipid-related metabolic complications of HIV disease.
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1. Introduction
HIV disease is characterized by severe metabolic complications including dyslipidemia and 
atherosclerosis [1, 2]. Adverse side-effects of antiretroviral regimens were originally blamed 
for these complications, however, as development of better treatment regimens with reduced 
effect on lipid metabolism did not eliminate dyslipidemia [3] and high risk of atherosclerosis 
[4], it is becoming increasingly clear that HIV disease itself makes a substantial contribution 
to the pathogenesis of these complications. We have demonstrated that HIV protein Nef 
inhibits cholesterol efflux causing cholesterol accumulation in HIV-infected macrophages 
[5]. The same effect was observed in uninfected cells treated with recombinant Nef or with 
plasma containing soluble Nef released from infected cells [6]. Furthermore, recombinant 
Nef injected in mice in vivo caused atherosclerosis and dyslipidemia supporting a key role 
of Nef in pathogenesis of HIV-associated metabolic abnormalities [7]. However, no clinical 
evidence supporting the role of Nef in lipid dysregulation is available.
In this study we analyzed plasma samples of six patients infected with Nef-deficient strain 
of HIV-1 (ΔNefHIV), all members of the Sydney Blood Bank Cohort (SBBC). 
Pathogenicity and immunogenicity of this strain have been described in previous 
publications [8–11] and summarized in a recent review [12]. In brief, all patients were 
infected with the same strain of HIV-1 through blood transfusion; they were slow-
progressors or non-progressors and remained asymptomatic for an extended period of time 
[12]. Lipid metabolism in these patients was never investigated and, considering a 
potentially key role of Nef in the pathogenesis of HIV related impairment of lipid 
metabolism, these patients provided a unique opportunity to elucidate the role of Nef in 
HIV-associated metabolic disorders in a clinical setting.
2. Methods
2.1. Patients
Patients infected with Nef-deficient strain of HIV-1 (ΔNefHIV, n=6) were all members of 
the SBBC cohort. Clinical and immunological parameters of these patients were originally 
described in several publications [8–11]; age, sex, CD4+ cell count and viral load values for 
these patients are shown in Table 1 in comparison to the same parameters in WT HIV 
subjects. All patients, except patient D36, were not receiving antiretroviral therapy. Two 
subjects (C49, C64) were postmenopausal females, all other patients were males.
Low et al. Page 2













The ΔNefHIV-infected patients were matched with patients infected with Nef-positive (WT) 
HIV-1 strain. Patients infected with Nef-positive strain of the virus (n=6) were selected from 
a cohort of treatment-naïve HIV patients described in our previous study [13]. All subjects 
were males. Reference values for HIV-negative subjects were obtained by analyzing plasma 
samples of six HIV negative subjects (all males) selected from a group of healthy volunteers 
from the blood bank of the Baker IDI Heart and Diabetes Institute.
All subjects were not undergoing any lipid-lowering therapy and did not have a history of 
cardiovascular disease. All samples were stored at −80°C and were analyzed retrospectively.
Plasma samples of both groups of HIV-infected patients used in this study were from the 
previous studies [9, 13]; original human ethics approvals permitted for the extension of 
analysis of the collected samples.
Lipoprotein profile—Total cholesterol (TC), low density lipoprotein cholesterol (LDL-
C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were analyzed 
using Cobas blood analyser. Apolipoprotein A-I and apolipoprotein B concentrations were 
analyzed using ELISA kits (Mabtech, Sweden).
2.2. HDL size
Distribution of apoA-I among HDL subfractions was analyzed by non-denaturing PAGE 
followed by immunoblotting using antibody against human apoA-I as described previously 
[14]. The following definitions of HDL subfractions were used: HDL3c, 7.2–7.8 nm; HDL3b, 
7.8–8.2 nm; HDL3a, 8.2–8.8 nm; HDL2a, 8.8–9.7 nm; HDL2b, 9.7–12 nm.
2.3. Cholesterol efflux
Cholesterol efflux assay was performed using THP-1 human macrophages activated with 
LXR agonist as described previously [15]. 1% plasma or 1.1% apoB-depleted plasma 
(obtained as described previously [15]) were used as an acceptor.
2.4. Lipidomic analysis
Lipidomic analysis was performed as described previously [16]. In brief, lipids from 10 μl of 
plasma were extracted using a modified, single phase Folch method; the analysis was done 
in triplicates. The analysis was performed by liquid chromatography electrospray ionization-
tandem mass spectrometry (LC ESI-MS/MS) using a Agilent 1200 liquid chromatography 
system, and Applied Biosystems API 4000 Q/TRAP mass spectrometer with a turbo-ion 
spray source (350 °C) and Analyst 1.5 and MultiQuant data systems using a Zorbax C18, 1.8 
μm, 50 × 2.1-mm column (Agilent Technologies). Lipid concentrations were calculated by 
relating the peak area of each species to the peak area of the corresponding internal standard.
2.5. Small RNA deep sequencing and bioinformatics analysis
RNA from plasma was extracted using the miRNeasy Mini Kit (Qiagen, Australia). The 
manufacturers’ protocol was followed with a slight modification involving the use of Trizol 
LS (Life Technologies, Australia). The small RNA yield, composition and quality was 
analyzed using the Agilent 2100 Bioanalyser with the Small RNA kit (Agilent 
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Technologies). Sequencing adapters were ligated onto the small RNA sample followed by 
conversion into cDNA libraries using the Ion Total RNA-Seq Kit V2 (Life Technologies, 
Australia) and prepared for deep sequencing on the Ion Torrent Personal Genome Machine 
(PGM™). Pooled libraries with unique barcodes were loaded on 318™ sequencing chips and 
run on the Ion Torrent PGM (Life Technologies, Australia) using the Ion PGM™ 200 
Sequencing Kit (Life Technologies). The Torrent Suite 4.2.1 was used to manage the Ion 
Torrent PGM™ to process raw signals and perform base calling. The sequences were then 
assessed for quality, and primer-adapter sequences were trimmed by the Torrent Suite 
software, followed by alignment to the human reference genome (HG19) using bowtie 2 
followed by a second pass through TMAP using Partek Flow. The trimmed and aligned data 
was mapped to known miRNA using miRBase V.20. The number of reads for each miRNA 
was adjusted to reads per million (RPM) and normalized using the lognormal linear method 
across all samples. Samples containing less than 5 reads per million were removed. The data 
was then transferred to Partek Genomics Suite for statistical analysis, hierarchical clustering 
and to identify unique miRNA in each sample type. TargetScan, mirDB and TarBase were 
interrogated to predict targets for the selected miRNAs. Raw sequencing files in .BAM 




Patient plasma lipoprotein and apolipoprotein levels are shown in Table 1. Total cholesterol, 
triglyceride and apolipoprotein B levels were similar between the groups, while LDL-C 
levels trended higher in WT HIV group. In comparison to a reference group of HIV-negative 
subjects level of HDL-C was reduced by 25% in WT HIV infected patients, but only by 8% 
in ΔNefHIV infected subjects, however, due to limited power of the study these substantial 
differences did not reach statistical significance. However, when we defined 
hypoalphalipoproteinemia (HALP) as HDL-C below 1 mmol/l, the proportion of subjects 
with HALP was significantly lower among patients infected with ΔNefHIV compared to 
those in WT HIV group (chi-square, P=0.05). Levels of apoA-I were similar in both HIV-
infected groups, consequently, the HDL-C/apoA-I ratio, which may be considered a 
surrogate marker of HDL lipidation, was 20% higher in ΔNefHIV patients, but again, the 
difference was not statistically significant.
3.2. HDL structure and functionality
We previously demonstrated that Nef reduces abundance and functionality of ABCA1 [5, 6, 
17]; the most likely consequence of this effect at systemic level would be changes in 
lipidation of HDL, which, in turn, may affect HDL functionality. An indication of this was a 
higher ratio of HDL-C/apoA-I in ΔNefHIV patients compared to HIV patients (Table 1). We 
therefore analyzed the distribution of HDL among particles of different sizes. In patients 
infected with WT HIV the proportion of large HDL2b particles (9.7–12 nm) was reduced 
relative to that in the reference group of uninfected subjects, whereas this effect was 
partially eliminated in patients infected with ΔNefHIV (Fig. 1A). The proportion of smaller 
HDL3a particles (8.2–8.8 nm) was increased in plasma of WT HIV infected patients, but not 
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in patients infected with ΔNefHIV. Proportion of HDL3b particles (7.8–8.2 nm) was 
increased in plasma of patients from both WT HIV and ΔNefHIV groups, while the 
proportion of smallest HDL3c particles (7.2–7.8 nm) was not affected by HIV status. Thus, 
HIV infection reduced the proportion of large fully lipidated HDL particles and increased 
the proportion of smaller under-lipidated HDL, this effect was partially eliminated in 
patients infected with ΔNefHIV.
To investigate the effect of these changes in HDL structure on HDL functionality, the ability 
of whole plasma and of HDL to support cholesterol efflux from human macrophages was 
tested. Macrophages were activated with LXR agonist to ensure that most of the efflux 
represents specific ABCA1/G1-dependent cholesterol efflux. When the efflux to whole 
plasma was tested, we found no statistically significant difference between the groups in the 
capacity of plasma to support cholesterol efflux (Fig. 1B). Next, we measured the efflux to 
plasma depleted of apoB-containing lipoproteins (i.e. plasma where HDL is the only 
available lipoprotein). We found that while there was no difference between the efflux to 
apoB-depleted plasma from HIV-negative subjects and subjects infected with ΔNefHIV, 
cholesterol efflux to plasma from WT HIV group was higher (Fig. 1C). We hypothesized 
that increased cholesterol efflux to HDL from WT HIV-infected subjects was due to 
increased proportion of small HDL3a particles, and indeed when data for all three groups 
were combined, there was a correlation between the capacity of HDL to support cholesterol 
efflux and proportion of HDL3a particles (r=0.50; p<0.05).
3.3. Lipidomic profiling
We have previously reported the effects of HIV infection on plasma lipidomic profile [16]. 
Using a similar approach, we compared lipidomic profile of patients infected with WT or 
Nef HIV. The full lipidomic profile (330 lipid species) is provided in the accompanying 
Data in Brief article [18], and lipid species significantly different between the groups are 
shown in Table 2. Compared to the reference group of uninfected subjects, three species of 
phosphatidylserine (PS) and PS as a group were reduced in WT HIV group, but not in 
ΔNefHIV group. Lipid species affected in ΔNefHIV group but not affected in WT HIV 
group, include individual species of dihydroceramide (dhCer), ceramide, 
alkylphosphatidylethanolamine, phosphatidylethanolamine (PE) and two species of 
sphingomyelin. Individual species of phosphatidylinositol and dhCer were increased in both 
HIV infected groups. One species each of dihexosylceramide, PE and PS were only 
increased in ΔNefHIV group.
When data for all three groups were combined, there was positive correlation between the 
proportion of HDL2a particles (which was similar in the three groups) and plasma 
abundance of phosphatidylcholine (r=0.69, p<0.002), cholesterol (r=0.54, p<0.05), 
alkenylphosphatidylcholine (r=0.47, p<0.05) and phosphatidylethanolamine (r=0.50, 
p<0.05); all these lipid species are major constituents of large lipidated HDL particles. There 
was also negative correlation between cholesterol efflux to whole plasma and the abundance 
of cholesteryl esters (r=−0.50, p<0.05) and ceramide (r=−0.45, p<0.05).
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Abundance of small RNAs extracted from plasma samples was analyzed by deep 
sequencing. RNA from two patients infected with ΔNefHIV did not pass quality control 
testing and were not sequenced. Unsupervised hierarchical clustering was performed on 
significantly differentially expressed miRNA using Euclidean average linkage by miRNA. 
The full dataset is presented in Supplemental Dataset 1, and differentially expressed 
miRNAs are shown in Fig. 2. Twenty-four miRNAs were found to be significantly 
deregulated in patients infected with WT HIV compared to the ΔNefHIV groups. These 24 
miRNAs were observed to show similar or recovered expression levels within ΔNefHIV and 
uninfected subject groups but were significantly deregulated in HIV patients. There are two 
major nodes of the dendrogram. Node 1 contains 4 miRNAs which were found to be up-
regulated in WT HIV group. Node 2 contains 20 miRNA which were found to be down-
regulated in WT HIV group. Predicted and validated targets for these miRNAs that are 
related to lipid metabolism and/or HIV infection are listed in Table 3.
4. Discussion
Metabolic complications are an important part of HIV disease and include impairment of 
cellular and systemic lipid metabolism and enhanced development of atherosclerosis. We 
have demonstrated the key role of HIV protein Nef in disturbances of cellular cholesterol 
metabolism caused by HIV infection [5]. Nef is an HIV accessory protein expressed early in 
infection; it is located on the plasma membrane of infected cells (for review see [19]) and is 
also released from infected cells. The documented effects of released Nef on uninfected cells 
include apoptosis [20], endothelial dysfunction [21], impairment of immune response [22], 
and impairment of cholesterol metabolism. The effects of extracellular Nef on lipid 
metabolism in bystander cells include down regulation of ABCA1 and inhibition of 
cholesterol efflux in vitro and hypoalphalipoproteinemia and hyperetrigliceridemia in vivo 
[6, 7]. Furthermore, Nef affects the spectrum of miRNAs released from infected cells in 
exosomes, including several miRNAs with established role in cholesterol metabolism, such 
as miR-33a*, miR-16b, miR-145, miR-144* [23]. Collectively, these findings suggest that 
Nef released from infected cells may be an important factor in pathogenesis of metabolic 
complications of HIV disease, but this concept was never tested in a clinical setting. Patients 
infected with ΔNefHIV provided a unique opportunity to close this gap.
The main finding of this study is a lower prevalence of hypoalphalipoprotenemia in patients 
infected with ΔNefHIV compared to patients infected with WT HIV. Furthermore, the 
proportion of smaller, presumably immature, HDL was increased in WT HIV infected 
patients similar to what was documented for SIV infection [6]. This effect was not observed 
in patients infected with ΔNefHIV. The HDL-C/apoA-I ratio trended to be higher in 
ΔNefHIV infected patients, also suggesting that HDL particles in these patients are more 
lipidated. These findings are consistent with our previous observations implicating Nef in 
reducing liver ABCA1 and impairing generation and/or maturation of HDL particles [6, 7]. 
There was no effect of HIV, with or without Nef, on the ability of whole plasma to support 
cholesterol efflux, which is consistent with our previous findings [3, 13]. However, when the 
efflux to HDL was measured, HDL from WT HIV group, but not from ΔNefHIV group, had 
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higher functionality in cholesterol efflux assay. The most likely explanation of this finding is 
higher proportion of small, presumably under-lipidated HDL particles in plasma of WT HIV 
infected patients compared to two other groups; small HDL particles are better acceptors of 
cholesterol compared to larger fully lipidated HDL particles [24]. This finding is 
inconsistent with findings of another recent study where the efflux to apoB-depleted plasma 
from WT HIV infected patients was reduced [25]; however, patient demographics in this 
study was different. Our hypothesis, however, is that the primary effect of extracellular Nef 
is in reducing abundance of ABCA1in both hepatic and extra-hepatic cells. In hepatocytes, 
reduction of ABCA1 would reduce plasma levels of HDL. In extra-hepatic cells, reduction 
of ABCA1 would reduce capacity of the cells for cholesterol efflux; contribution of the 
inhibition of ABCA1 in macrophages used in this study was not tested as cells were neither 
infected with HIV nor treated with Nef.
Lipidomic analysis of patient plasma showed a significant difference between WT HIV and 
uninfected subjects as well as between WT HIV and ΔNefHIV groups in several species of 
phosphatidylserine. The lower level of phosphatidylserine in plasma from WT HIV group 
relative to ΔNefHIV groups may reflect different circulating microparticle levels in these 
groups. Phosphatidylserine is a major lipid in the platelet plasma membrane and in platelet 
derived microparticles, thus the lower level observed in plasma of WT HIV group may 
reflect a role of Nef in suppressing platelet activation and/or microparticle production. Also 
of interest is the lipid species that show a significant difference between the uninfected 
group and the ΔNefHIV group, but no difference between uninfected and WT HIV groups. 
These lipids include primarily sphingolipids (dihexosylceramide, ceramide and 
sphingomyelin) which were elevated in the ΔNefHIV infected patients. We have previously 
reported that ceramides, while not associated with HIV itself, are positively associated with 
risk of future cardiovascular events in HIV infected individuals, and that sphingomyelin, 
which was negatively associated with WT HIV, also showed a positive association with 
future cardiovascular events [16].
Profiling of plasma miRNA showed that the abundance of 24 miRNAs was likely dependent 
on the presence of Nef. Predicted targets of these miRNAs included ABCA1 itself (hsa-
miR-199b-3p) and two factors directly involved in regulation of ABCA1 abundance, 
ABCA12 (hsa-miR-409-3p) [26] and calnexin (hsa-miR-320a) [27]. MicroRNAs apparently 
regulated by Nef were also predicted to target a number of other ABC transporters 
(ABCA10, ABCA13, ABCB9), lipoprotein receptors (LDL receptor, VLDL receptor, 
several members of LDL receptor related protein family) and ligands (apolipoprotein A-II) 
and enzymes involved in lipid biosynthesis (members of long-chain acyl-CoA synthetase 
family, neutral sphingomyelinase). Fifteen of these miRNAs, or their close homologs, were 
also found to be regulated by Nef in exosomes released from Nef-transfected cells [23], 
although the direction of change was not always the same. Despite relatively large changes 
in the abundance of these miRNAs, this did not cause profound changes in plasma 
lipoprotein profile. However, the target cells of these miRNA are not necessarily the cells 
involved in regulation of plasma lipoprotein metabolism, but may be cells where changes in 
intracellular cholesterol metabolism play a role in pathogenesis of common complications of 
HIV, such as cells of vessel wall involved in atherosclerosis or β-cells involved in diabetes. 
Thus, within a limitation of analysis restricted to circulating miRNAs and the fact that not 
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all targets were validated, our findings are consistent with a hypothesis that alteration of 
expression and/or release of miRNAs may be an important mechanism by which HIV Nef 
dysregulates lipid metabolism in HIV disease.
5. Limitations
This study has several important limitations. First, the group size of ΔNefHIV infected 
patients was small. Unfortunately, the cohort of these patients is unique and no more 
patients infected with ΔNefHIV are known to us, therefore, this cohort could not be 
expanded. A change in the treatment guidelines shifting initiation of treatment to primary 
care also prevented expansion of the matching treatment-naïve WT HIV group. The 
ΔNefHIV group included two female patients, but both were of postmenopausal age, 
therefore, this should not have greatly affected the results. Plasma samples from patients of 
ΔNefHIV group were collected at a different time and by different operators and were stored 
for longer time compared to samples in WT HIV group, potentially contributing to the 
observed variability. Finally, infection with Nef-deficient HIV resulted in much lower viral 
loads and in a milder presentation of several elements of immunologic dysfunction 
compared to patients infected with WT HIV. This makes it difficult to distinguish between 
the direct effects of the deficiency of Nef and indirect effects of milder impairment of 
immunologic status and lower viral load. This compromise is difficult to avoid as viral loads 
similar to those in patients infected with ΔNefHIV are only achievable after effective 
treatment with HAART, which would represent an even bigger confounding factor. Despite 
these limitations, the findings of this study support the hypothesis that Nef secreted from 
HIV infected cells plays, directly or indirectly, a major role in pathogenesis of metabolic 
complications of HIV disease.
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• Patients infected with Nef-deficient strain of HIV(ΔNefHIV) have reduced 
prevalence of hypoalphalipoproteinema
• Several lipid classes in plasma lipidomic profile are different in patients infected 
with WT HIV and ΔNefHIV
• HIV induced changes in profile of lipid metabolism related microRNA are 
attenuated in ΔNefHIV patients
• Findings are consistent with Nef playing a significant role in lipid abnormalities 
in HIV patients
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Figure 1. The effect of HIV and ΔNefHIV infection on the structure (A) and function (B, C) of 
plasma high density lipoprotein
A – Analysis of distribution of HDL among different subfractions in plasma of HIV-
negative subjects and patients infected with WT HIV or ΔNefHIV. *p<0.05; **p<0.01 
versus HIV negative subjects. B- Cholesterol efflux from human THP-1 monocyte-
macrophages to 1% plasma from HIV-negative subjects and patients infected with WT HIV 
or ΔNefHIV. C- Cholesterol efflux from human THP-1 monocyte-macrophages to 1.1% 
apoB-depleted plasma from HIV-negative subjects and patients infected with WT HIV or 
ΔNefHIV. *p<0.05 versus HIV-negative; #p<0.05 versus ΔNefHIV.
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Figure 2. Hierarchical clustering of differentially regulated miRNA in WT HIV and ΔNefHIV 
patients
Abundance of miRNAs that show similar or recovered expression levels within ΔNefHIV 
patients and uninfected patients however significantly deregulated in HIV patients. Lines 
connect pairs with p<0.01.
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Table 2
Lipidomic analysis
Lipid Species HIV Negative WT HIV ΔNef-HIV
PS 36:1 1418.5 ± 935.8 259.5 ± 259.9** 7733.5 ± 9425.3#
PS 38:3 299.8 ± 158.4 53.8 ± 91.9* 1559.4 ± 1791.7#
PS 40:5 123.0 ± 65.5 13.6 ± 33.4** 590.9 ± 659.4#
PS (total) 2161.5 ± 1317.7 334.2 ± 121.4* 10,772.2 ± 12,619.5#
dhCer 20:0 20.8 ± 5.6 23.4 ± 9.1 115.7 ± 125.8*
Cer 18:0 80.4 ± 16 102.9 ± 26.6 140.7 ± 76.9*
SM 32:0 423.0 ± 84.8 512.0 ± 136.4 666.2 ± 176.0*
SM 34:0 4,369 ± 686.2 5,402.1 ± 1,442.6 6,326 ± 803.1**
PE(O-36:6) 34.3 ± 10.4 71.7 ± 44.9 95.4 ± 32.5**
dhCer (total) 519.0 ± 77.7 571.9 ± 254.3 1439.2 ± 1033.8*
PI 34:0 153.5 ± 58.0 362.2 ± 298.8* 342.8 ± 287.7
dhCer 16:0 46.3 ± 6.7 71.5 ± 15.7* 120.7 ± 70.5**
dhCer 18:0 46.1 ± 11.4 79.6 ± 22.0* 194.1 ± 184.3*
DHC 20:0 111.3 ± 38.4 85.0 ± 38.6 256.2 ± 249.5#
PE(22:6/0:0) 1378.0 ± 402.6 1723.5 ± 836.7 1042.8 ± 168.4#
PS 40:6 128.4 ± 53.9 36.6 ± 49.7 572.1 ± 619.6#
Abbreviations: dhCer, dihydroceramide; Cer, ceramide; DHC, dihexosylceramide; PE, phosphatidylethanolamine; PE(O), 
alkylphosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin;
*
p < 0.05 vs HIV Negative;
**
p < 0.01 vs HIV Negative;
#
p < 0.05 vs WT HIV (ANOVA)
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